Susquehanna analyst James Friedman lowered the firm’s price target on Endava to $112 from $120 and keeps a Positive rating on the shares. The analyst said In light of recent peer group commentary, macro developments, and read-throughs, we are lowering near-term estimates modestly.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DAVA: